¼¼°èÀÇ ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀå : ¹é½Å À¯Çüº°, ¿¬·ÉÃþº°, Åõ¿© °æ·Îº°, À¯Åë ä³Îº° ¿¹Ãø(2025-2030³â)
Influenza Vaccine Market by Vaccine Type (Inactivated, Live Attenuated, Recombinant), Age Group (Adolescent Vaccination, Adult Vaccination, Infant Vaccination), Administration Route, Distribution Channel - Global Forecast 2025-2030
»óǰÄÚµå : 1592909
¸®¼­Ä¡»ç : 360iResearch Private Limited
¹ßÇàÀÏ : 2024³â 10¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 191 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,939 £Ü 5,699,000
PDF, Excel & 1 Year Online Access (Single User License) help
PDF ¹× Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù. ¿Â¶óÀÎ Ç÷§Æû¿¡¼­ 1³â µ¿¾È º¸°í¼­¸¦ ¹«Á¦ÇÑÀ¸·Î ´Ù¿î·ÎµåÇÒ ¼ö ÀÖÀ¸¸ç, Á¤±âÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ´Â Á¤º¸µµ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. (¿¬ 3-4ȸ Á¤µµ ¾÷µ¥ÀÌÆ®)
US $ 4,249 £Ü 6,147,000
PDF, Excel & 1 Year Online Access (2-5 User License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿Àϱâ¾÷ ³» 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù. ¿Â¶óÀÎ Ç÷§Æû¿¡¼­ 1³â µ¿¾È º¸°í¼­¸¦ ¹«Á¦ÇÑÀ¸·Î ´Ù¿î·ÎµåÇÒ ¼ö ÀÖÀ¸¸ç, Á¤±âÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ´Â Á¤º¸µµ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. (¿¬ 3-4ȸ Á¤µµ ¾÷µ¥ÀÌÆ®)
US $ 5,759 £Ü 8,332,000
PDF, Excel & 1 Year Online Access (Site License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» µ¿ÀÏ Áö¿ª »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù. ¿Â¶óÀÎ Ç÷§Æû¿¡¼­ 1³â µ¿¾È º¸°í¼­¸¦ ¹«Á¦ÇÑÀ¸·Î ´Ù¿î·ÎµåÇÒ ¼ö ÀÖÀ¸¸ç, Á¤±âÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ´Â Á¤º¸µµ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. (¿¬ 3-4ȸ Á¤µµ ¾÷µ¥ÀÌÆ®)
US $ 6,969 £Ü 10,083,000
PDF, Excel & 1 Year Online Access (Enterprise User License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù. ¿Â¶óÀÎ Ç÷§Æû¿¡¼­ 1³â µ¿¾È º¸°í¼­¸¦ ¹«Á¦ÇÑÀ¸·Î ´Ù¿î·ÎµåÇÒ ¼ö ÀÖÀ¸¸ç, Á¤±âÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ´Â Á¤º¸µµ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. (¿¬ 3-4ȸ Á¤µµ ¾÷µ¥ÀÌÆ®)


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀåÀº 2023³â¿¡ 79¾ï 2,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³â¿¡´Â 86¾ï 1,000¸¸ ´Þ·¯¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 9.01%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 144¾ï 9,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀåÀº ÀÎÇ÷翣ÀÚ ¹ÙÀÌ·¯½ºÀÇ È®»êÀ» ¹æÁöÇϱâ À§ÇÑ ¹é½ÅÀÇ °³¹ß, »ý»ê ¹× À¯ÅëÀ» Æ÷°ýÇϰí ÀÖ½À´Ï´Ù. ÀÌ ½ÃÀåÀº ¼¼°èÀûÀ¸·Î ½É°¢ÇÑ °Ç°­ ¹®Á¦¸¦ ÀÏÀ¸Å°´Â °èÀý¼º µ¶°¨ÀÇ ¹ß»ýÀ» ¾ïÁ¦ÇÒ Çʿ伺¿¡ ÀÇÇØ °ßÀεǰí ÀÖ½À´Ï´Ù. ÁÖ¿ä ¿ëµµ´Â Á¤ºÎÀÇ º¸°ÇºÎ¹®, ÀÇ·á½Ã¼³, ¹Î°£ Ŭ¸®´ÐÀÌ ¿î¿µÇÏ´Â ¿¹¹æÁ¢Á¾ ÇÁ·Î±×·¥À̸ç, ÃÖÁ¾ ¿ëµµ´Â ¸ðµç ¿¬·ÉÃþÀÇ °³ÀÎ, ƯÈ÷ ³ëÀÎ, À¯¾Æ, ¸é¿ª·ÂÀÌ ÀúÇÏµÈ »ç¶÷ µî Ãë¾à ÇÑ »ç¶÷µé¿¡ À̸¨´Ï´Ù. ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÁÖ¿ä ¿äÀÎÀ¸·Î´Â ÀÎÇ÷翣ÀÚ ¹é½Å Á¢Á¾ ÇÁ·Î±×·¥¿¡ ´ëÇÑ Á¤ºÎ ¹× ¹Î°£ ÅõÀÚ Áõ°¡, ¹é½Å ±â¼úÀÇ Áö¼ÓÀûÀÎ Áøº¸, °èÀý¼º ÀÎÇ÷翣ÀÚ°¡ °Ç°­¿¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ ´ëÇÑ ÀÇ½Ä Áõ°¡ µîÀÌ ÀÖ½À´Ï´Ù. ½ÃÀå °³Ã´ÀÇ ±âȸ·Î´Â ½ÅÈï±¹ ½ÃÀåÀÇ È®´ë, Æø³ÐÀº ¿¹¹æ È¿°ú¸¦ Á¦°øÇÏ´Â 4°¡ ¹é½Å¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ÁÖ»ç ¹Ù´ÃÀ» »ç¿ëÇÏÁö ¾Ê´Â ¹é½Å Åõ¿© µî Çõ½ÅÀûÀÎ Åõ¿© ¹æ¹ýÀ» µé ¼ö ÀÖ½À´Ï´Ù. À̸¦ Ȱ¿ëÇϱâ À§ÇØ ±â¾÷Àº º¸´Ù È¿°úÀûÀÌ°í º¸È£±â°£ÀÌ ±ä ¹é½ÅÀÇ °³¹ß°ú ¹é½ÅÁ¢Á¾·üÀ» ³ôÀ̱â À§ÇÑ ±³À° Ä·ÆäÀÎÀÇ È®´ë¿¡ ÁÖ·ÂÇØ¾ß ÇÕ´Ï´Ù. ±×·¯³ª ½ÃÀå ¼ºÀåÀº ¿¹¹æ Á¢Á¾, ÁÖ¸ñÇÒ¸¸ÇÑ R&D ºñ¿ë, È¿°úÀûÀÎ ¹é½Å ó¹æÀ»À§ÇÑ ¹Ì·¡ ÀÎÇ÷翣ÀÚ ±ÕÁÖÀÇ ¿¹Ãø º¹À⼺°ú °°Àº ¹®Á¦¿¡ Á÷¸é ÇØ ÀÖ½À´Ï´Ù. ¶ÇÇÑ ±ÔÁ¦»óÀÇ Àå¾Ö¹°°ú Á¦³×¸¯ Á¦Á¶¾÷ü¿ÍÀÇ °æÀïÀ¸·Î ÀÎÇÑ ÇѰ赵 ¹ß»ýÇϰí ÀÖ½À´Ï´Ù. mRNA ±â¼úÀÇ ÀÌ¿ë, ¹é½Å º¸Á¸ ¼Ö·ç¼ÇÀÇ °­È­, ½Å¼ÓÇÑ ¹é½Å Á¦Á¶ ¹æ¹ýÀÇ °³¼± µîÀÇ ºÐ¾ß¿¡¼­ÀÇ ±â¼ú Çõ½ÅÀº Å« Áøº¸¸¦ °¡Á®¿Ã ¼ö ÀÖ½À´Ï´Ù. °á±¹ ÀÌ ½ÃÀå Æ¯Â¡Àº ÀÎÇ÷翣ÀÚ ±ÕÁÖÀÇ µ¹¿¬º¯À̰¡ ¹Ýº¹µÇ°í Ç×»ó ÃÖ½ÅÀÇ ¹é½ÅÀÌ ¿ä±¸µÇ´Â ¿ªµ¿ÀûÀÎ ¼ºÁú¿¡ ÀÖ¾î Á¦Ç°ÀÇ Â÷º°È­¿Í ½ÃÀå ħÅõ¸¦ À§ÇÑ Áö¼ÓÀûÀÎ ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Ãø¸éÀ» ÀÌÇØÇÔÀ¸·Î½á, ÀÌ ºÐ¾ßÀÇ ±â¾÷Àº Áö¼Ó °¡´ÉÇÑ ºñÁî´Ï½º ¼ºÀåÀ» °¡¼ÓÇϱâ À§ÇÑ °úÁ¦¿Í ±âȸ¸¦ Àü·«ÀûÀ¸·Î Ž»öÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ(2023) 79¾ï 2,000¸¸ ´Þ·¯
¿¹Ãø³â(2024) 86¾ï 1,000¸¸ ´Þ·¯
¿¹Ãø³â(2030) 144¾ï 9,000¸¸ ´Þ·¯
º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)(%) 9.01%

½ÃÀå ¿ªÇÐ : ºü¸£°Ô ÁøÈ­ÇÏ´Â ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ º¯¸ð¸¦ ÀÌ·ç°í ÀÖ½À´Ï´Ù. ±×¸®°í »õ·Î¿î ºñÁî´Ï½º ±âȸ ȹµæ¿¡ ´ëºñÇÏ´Â °Í ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦ÀûÀÎ ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ °æ°¨ÇÒ ¼ö ÀÖÀ½°ú µ¿½Ã¿¡ ¼ÒºñÀÚ Çൿ°ú ±×°Í Á¦Á¶ ºñ¿ë°ú ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ»º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

Porter's Five Forces : ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸

Porter's Five Forces Framework´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Porter's Five Forces Framework´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ ޱ¸ÇÏ´Â ¸íÈ®ÇÑ ±â¼úÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÀλçÀÌÆ®À» ÅëÇØ ±â¾÷Àº ÀÚ»çÀÇ °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ °úÁ¦¸¦ ÇÇÇÒ ¼ö ÀÖÀ¸¸ç, º¸´Ù °­ÀÎÇÑ ½ÃÀå¿¡¼­ÀÇ Æ÷Áö¼Å´×À» º¸ÀåÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀå¿¡¼­ ¿ÜºÎ ¿µÇâÀ» ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇϴµ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀÎ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¾ÕÀ¸·Î ¿¹»óµÇ´Â Àû±ØÀûÀÎ ÀÇ»ç °áÁ¤À» ÇÒ Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀå °æÀï ±¸µµ ÆÄ¾Ç

ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü µî ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀï Æ÷Áö¼Å´×À» ¹àÈú ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ½ÃÀå ÁýÁß, ´ÜÆíÈ­, ÅëÇÕ µ¿ÇâÀ» ¹àÇô³»°í º¥´õµéÀº °æÀïÀÌ Ä¡¿­ÇØÁö´Â °¡¿îµ¥ ÀÚ»çÀÇ ÁöÀ§¸¦ ³ôÀÌ´Â Àü·«Àû ÀÇ»ç °áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ Áö½ÄÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀå¿¡¼­ °ø±Þ¾÷üÀÇ ¼º´É Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀå¿¡¼­ º¥´õ¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ±âº» °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. ³× °¡Áö »çºÐ¸éÀ» ÅëÇØ º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ºÐÇÒÇϰí Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê ¹× ¼Ö·ç¼ÇÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× ±ÇÀå ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀå¿¡¼­ ¼º°ø¿¡ ´ëÇÑ ±æÀ» ±×¸³´Ï´Ù.

ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀåÀÇ Àü·«Àû ºÐ¼®Àº ½ÃÀå¿¡¼­ÀÇ ÇÁ·¹Á𽺠°­È­¸¦ ¸ñÇ¥·Î ÇÏ´Â ±â¾÷¿¡ ÇʼöÀûÀÎ ¿ä¼ÒÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀ» ÅëÇØ °æÀï ±¸µµ¿¡¼­ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ üÁ¦¸¦ ±¸ÃàÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀåÀÇ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ : ½ÅÈï ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡ÇÏ¸ç ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù¾çÈ­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä Áøº¸, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú Áøº¸ µîÀ» °ËÁõÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÃÖ÷´Ü ±â¼ú, R&D Ȱµ¿, Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚ°¡ ÃæºÐÇÑ Á¤º¸¸¦ ¾ò°í ÀÇ»ç°áÁ¤À» ÇÒ ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡ ´ë´äÇϰí ÀÖ½À´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå ¿¹ÃøÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹® ¹× Áö¿ªÀº ¾îµðÀԴϱî?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ, ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

Á¦6Àå ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀå : ¹é½ÅÀ¯Çüº°

Á¦7Àå ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀå : ¿¬·ÉÃþº°

Á¦8Àå ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀå Åõ¿© °æ·Îº°

Á¦9Àå ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀå : À¯Åë ä³Îº°

Á¦10Àå ¾Æ¸Þ¸®Ä« ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀå

Á¦11Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀå

Á¦12Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀå

Á¦13Àå °æÀï ±¸µµ

±â¾÷ ¸ñ·Ï

BJH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The Influenza Vaccine Market was valued at USD 7.92 billion in 2023, expected to reach USD 8.61 billion in 2024, and is projected to grow at a CAGR of 9.01%, to USD 14.49 billion by 2030.

The influenza vaccine market encompasses the development, production, and distribution of vaccines designed to prevent the spread of influenza viruses. This market is driven by the necessity to control seasonal flu outbreaks, which result in significant health challenges globally. The primary applications include immunization programs run by government health departments, healthcare facilities, and private clinics, while the end-use scope extends to individuals across all age groups, especially vulnerable populations such as the elderly, young children, and those with weakened immune systems. Key influencing growth factors include increased government and private investments in flu vaccination programs, continuous advancements in vaccine technology, and heightened awareness about seasonal influenza's health impacts. Opportunities within the market are notably led by emerging markets in developing nations, rising demand for quadrivalent vaccines offering broader protection, and innovative delivery methods such as needle-free vaccine administrations. To capitalize on these, businesses should focus on developing more effective vaccines with longer durations of protection and expanding educational campaigns to boost vaccination rates. However, market growth faces challenges like vaccine hesitancy, high research and development costs, and the complexity of predicting future influenza strains for effective vaccine formulation. Limitations also arise from regulatory hurdles and competition from generic manufacturers. Innovating in areas such as the use of mRNA technology, enhancing vaccine storage solutions, and improving rapid vaccine production methods could drive significant advancements. Ultimately, the market is characterized by its dynamic nature, necessitated by recurring influenza strain mutations and the constant requirement for updated vaccines, providing ongoing opportunities for product differentiation and market penetration. Understanding these facets, companies in the sector can strategically navigate the challenges and opportunities to drive sustainable business growth.

KEY MARKET STATISTICS
Base Year [2023] USD 7.92 billion
Estimated Year [2024] USD 8.61 billion
Forecast Year [2030] USD 14.49 billion
CAGR (%) 9.01%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Influenza Vaccine Market

The Influenza Vaccine Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

Porter's Five Forces: A Strategic Tool for Navigating the Influenza Vaccine Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Influenza Vaccine Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Influenza Vaccine Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Influenza Vaccine Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Influenza Vaccine Market

A detailed market share analysis in the Influenza Vaccine Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Influenza Vaccine Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Influenza Vaccine Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Influenza Vaccine Market

A strategic analysis of the Influenza Vaccine Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Influenza Vaccine Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AstraZeneca PLC, Bayer AG, BioDiem, BiondVax Pharmaceuticals Ltd., Bristol-Myers Squibb Company, CanSino Biologics Inc., Daiichi Sankyo Company, Limited, Emergent BioSolutions Inc., Eurocept Group, Fluart Innovative Vaccines Kft., Gamma Vaccines Pty Ltd, GlaxoSmithKline PLC, Johnson & Johnson, Merck & Co., Inc., Pfizer Inc., Sanofi S.A., Seqirus GmbH, Serum Institute of India Pvt. Ltd., Sinovac Biotech Ltd., and Swedish Orphan Biovitrum AB.

Market Segmentation & Coverage

This research report categorizes the Influenza Vaccine Market to forecast the revenues and analyze trends in each of the following sub-markets:

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

6. Influenza Vaccine Market, by Vaccine Type

7. Influenza Vaccine Market, by Age Group

8. Influenza Vaccine Market, by Administration Route

9. Influenza Vaccine Market, by Distribution Channel

10. Americas Influenza Vaccine Market

11. Asia-Pacific Influenza Vaccine Market

12. Europe, Middle East & Africa Influenza Vaccine Market

13. Competitive Landscape

Companies Mentioned

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â